Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-50

Hey Index,

Why's that date significant?

I would also doubt RAC is the only company competing for the same slice of the pie as I assume also that Amgen have many synergetic drugs with Kyprolis that could extend their patent life. Cardio protective or not they (Amgen) will need to take the next step as RAC stated they won't be taking it further. Not sure if it's a ballsie move from RAC or a waste of money. Why do the preclinical work with carfilzomib in the first place to leave it here? What am I missing? Have we really got a chance with Amgen?